The biological properties of the CD147 antigen allow CD147-CAR-modified immune cells, including primary CD8+ T, primary NK, and NK-92MI cells, to produce potent anti-tumor activity against HCC in vitro and in vivo. This evidence concerns the gene BSG and hepatocellular carcinoma.